Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study analysing safey and efficacy of pembrolizumab plus chemotherapy to pembrolizumab monotherapy in advanced NSCLC patients

Next Previous
X
Search
Trial Profile

A study analysing safey and efficacy of pembrolizumab plus chemotherapy to pembrolizumab monotherapy in advanced NSCLC patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 01 Mar 2022 Results comparing efficacy and safety of pembrolizumab plus chemotherapy and monotherapy, published in the Cancer Immunology Immunotherapy
    • 08 Jun 2021 Results comparing time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy in NSCLC patients, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 15 Oct 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top